{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:25:17Z","timestamp":1787034317358,"version":"build-2736575974"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Macrophage activation syndrome (MAS) is a severe, life-threatening complication in pediatric rheumatic diseases. Current treatments are predominantly based on glucocorticoids; however, their long-term use is associated with significant adverse effects. Ruxolitinib, a Janus kinase (JAK) inhibitor, has emerged as a potential treatment option, but clinical evidence in pediatric populations remains limited. This study aimed to evaluate its efficacy and safety in pediatric patients with rheumatic disease-associated MAS (RD-MAS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed the medical records of pediatric patients with RD-MAS treated at Shenzhen Children\u2019s Hospital between January 2021 and December 2025. Eligible patients had a confirmed rheumatic disease, fulfilled the 2016 EULAR\/ACR classification criteria for MAS, and had complete clinical, laboratory, treatment, and follow-up data. Patients who received ruxolitinib in addition to conventional immunosuppressive therapy were compared with contemporaneous patients treated with conventional immunosuppressive therapy alone. The primary outcome was time to complete remission (CR). Secondary outcomes included remission rates during follow-up, changes in laboratory parameters, glucocorticoid-sparing effect, cumulative glucocorticoid exposure, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 21 patients with RD-MAS were included, of whom 10 received ruxolitinib (ruxolitinib group) and 11 received conventional therapy alone (non-ruxolitinib group). In the ruxolitinib group, 10 patients (6 males, 4 females) had underlying diagnoses of systemic juvenile idiopathic arthritis (sJIA, n = 7), systemic lupus erythematosus (SLE, n = 1), or other connective tissue diseases (n = 2). All patients presented with active disease at baseline. 30% (3\/10) of patients achieved CR by week 4, and all patients achieved CR by week 48. By week 8, the median prednisone-equivalent dose decreased from 4 mg\/kg\/day to 0.4 mg\/kg\/day, and all patients successfully discontinued glucocorticoids by week 48 while maintaining remission. No significant difference in time to CR or infection rates was observed between groups. However, the ruxolitinib group demonstrated significantly lower cumulative glucocorticoid exposure during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ruxolitinib-based therapy was associated with sustained disease control and a significant glucocorticoid-sparing effect in pediatric RD-MAS. These findings support that ruxolitinib may serve as a promising steroid-sparing strategy with favorable efficacy and safety for pediatric RD-MAS, although larger prospective studies are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1852538","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:37:11Z","timestamp":1787031431000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ruxolitinib for rheumatic disease-associated macrophage activation syndrome in children: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaona","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Shenzhen Children\u2019s Hospital Affiliated Shenzhen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shenzhen Children\u2019s Hospital Affiliated Shenzhen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shenzhen Children\u2019s Hospital Affiliated Shenzhen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shenzhen Children\u2019s Hospital Affiliated Shenzhen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/art.43052","article-title":"Macrophage activation syndrome","volume":"77","author":"Nigrovic","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab673","article-title":"Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA)","volume":"61","author":"Verweyen","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70082","article-title":"Efficacy of etoposide-based therapy in pediatric secondary hemophagocytic lymphohistiocytosis","volume":"116","author":"Tahta","year":"2026","journal-title":"Eur J Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"De Benedetti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/art.43263","article-title":"Impact of interleukin-1 blockade on the development of macrophage activation syndrome in still disease: incidence and diagnostic validity of the EULAR\/ACR\/PRINTO 2016 MAS classification criteria","volume":"77","author":"Erkens","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000761","article-title":"Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis","volume":"134","author":"Albeituni","year":"2019","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208982","article-title":"2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation collaborative initiative","volume":"75","author":"Ravelli","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1604648","article-title":"Efficacy and safety of ruxolitinib in adult patients with refractory rheumatic disease-associated macrophage activation syndrome","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","article-title":"Glucocorticoid-induced osteoporosis: an update","volume":"61","author":"Compston","year":"2018","journal-title":"Endocrine"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad474","article-title":"Unintended consequences: risk of opportunistic infections associated with long-term glucocorticoid therapies in adults","volume":"78","author":"Chastain","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000804","article-title":"Glucocorticoid withdrawal syndrome: what to expect and how to manage","volume":"30","author":"Theiler-Schwetz","year":"2023","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12969-021-00534-0","article-title":"Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis","volume":"19","author":"Chi","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024362","article-title":"Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome","volume":"146","author":"Ma","year":"2025","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2024.2384042","article-title":"Breaking the storm: ruxolitinib as a lifeline in refractory hemophagocytic lymphohistiocytosis with macrophage activation syndrome","volume":"38","author":"Escobar Gil","year":"2025","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226433","article-title":"Ruxolitinib as a salvage therapy in adult-onset macrophage activation syndrome: insights from eight cases","volume":"83","author":"Song","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026139","article-title":"Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China","volume":"146","author":"Zhou","year":"2025","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.253781","article-title":"A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis","volume":"106","author":"Zhang","year":"2021","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70429","article-title":"Janus kinase inhibitors during pregnancy and adverse drug reactions: a pharmacovigilance disproportionality analysis in VigiBase","volume":"18","author":"Abolhassani","year":"2025","journal-title":"Clin Transl Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"10.1002\/cpt.70367","DOI":"10.1002\/cpt.70367","article-title":"Ruxolitinib pharmacokinetics and exposure-toxicity relationship in hematologic Malignancies and immune-mediated diseases: a prospective observational study","volume":"24","author":"Tachet","year":"2026","journal-title":"Clin Pharmacol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.03.030","article-title":"Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19","volume":"28","author":"Girardin","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2023.123917","article-title":"Development and validation of a multiplex HPLC-MS\/MS assay for the monitoring of JAK inhibitors in patient plasma","volume":"1230","author":"Tachet","year":"2023","journal-title":"J Chromatogr B Analyt Technol BioMed Life Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1852538\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:37:11Z","timestamp":1787031431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1852538\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2026.1852538"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1852538","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1852538"}}